Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist used to treat MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals reported in the Journal of Hepatology that a pre-specified secondary analysis of the Phase 3 MAESTRO-NASH trial found Rezdiffra, also known as resmetirom, improved fibrosis, MASH resolution, liver fat and biomarker levels across patients regardless of common genetic risk variants including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7, with safety consistent with the overall study. The company said Rezdiffra's thyroid hormone receptor-beta mechanism appeared unaffected by these genetic risk pathways, suggesting the drug's benefit may extend broadly across genetically diverse MASH populations. Madrigal is also pursuing a precision-medicine PNPLA3 siRNA program, having recently added MGL-0795, a PNPLA3-targeting siRNA, to its pipeline alongside the existing Pfizer DGAT2 combo program. The company's narrative projects $3.2 billion in revenue and $935.6 million in earnings by 2029, requiring 42.0% yearly revenue growth and about a $1.25 billion earnings increase from -$309.4 million today, while more optimistic analysts assume about US$3.6 billion in revenue and US$1.5 billion in earnings by 2028.
Novo Nordisk Expands Semaglutide Beyond Cardiometabolic Care as Lilly Rivalry Intensifies
Novo Nordisk is pushing to extract greater value from semaglutide by expanding its use beyond traditional diabetes, obesity and cardiovascular indications, even as it faces intense competition from Eli Lilly across cardiometabolic care. Semaglutide-based GLP-1 products, including Ozempic and Rybelsus for type II diabetes and Wegovy for obesity, accounted for roughly 75.5% of Novo's adjusted first-half 2026 sales, leaving the company highly exposed to changes in competition, pricing and market share. The clearest example of the expansion came with Wegovy's 2025 U.S. approval for noncirrhotic metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced liver fibrosis, and in March 2026 the European Commission granted conditional authorization to Kayshild, or semaglutide, for adults with noncirrhotic MASH and F2-F3 liver fibrosis. Novo is also building evidence in knee osteoarthritis, where the STEP 9 study showed significant improvements in pain and physical function among adults with obesity, and in post-hoc analyses of obstructive sleep apnea and asthma-related outcomes, though these remain opportunities rather than established indications. The company's Alzheimer's disease program for semaglutide was discontinued after the phase III EVOKE and EVOKE+ studies failed to meet their primary endpoints. Eli Lilly is pursuing a similarly broad strategy, with Mounjaro approved in the United States to reduce major cardiovascular events in adults with T2D at high cardiovascular risk, Zepbound approved for adults with obesity and moderate-to-severe OSA, the oral GLP-1 pill Foundayo being studied across multiple conditions, and retatrutide in late-stage studies. In MASH, Madrigal Pharmaceuticals' Rezdiffra generated $675.6 million in first-half 2026 sales, up 93% year over year, while Altimmune's pemvidutide is in the phase III PERFORMA study with a potential 52-week readout not expected until 2029. Year to date, Novo shares have lost 26.2% against the industry's 8.9% growth, and the stock trades at 10.92 forward earnings versus 17.49 for the industry, while 2026 earnings estimates have risen from $3.40 to $3.53 per share over the past 60 days.
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
Aging Population › Chronic-Disease Pharma Franchises Competition
Longevity & Life Extension › GLP-1 Healthspan Proxies Competition
NVO · Technology · Positive Wegovy's U.S. MASH approval and EU conditional authorization of Kayshild expand semaglutide beyond cardiometabolic indications
LLY · Competition · Negative Novo Nordisk is expanding semaglutide into new indications, intensifying rivalry with Lilly across cardiometabolic care
MDGL · Competition · Neutral Madrigal's Rezdiffra MASH sales cited as context in the GLP-1 MASH competition landscape
Arrowhead's Plozasiran Launch and Q3 Results Could Drive Re-rating
Arrowhead Pharmaceuticals, Inc. (ARWR) reached a major European milestone on August 17 when it announced the availability of REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany, following European Commission authorization in June 2026. The drug is now listed in the Lauer-Taxe database for prescribing and reimbursement, and can be prescribed once every three months based on clinical symptoms or genetic tests. This launch expansion comes shortly after Arrowhead reported its fiscal Q3 2026 financial results on August 4, with quarterly revenue surging 171% year-over-year to $75.3 million, beating Wall Street expectations of $52.7 million, driven by collaboration income and doubling REDEMPLO U.S. prescription volume. Net loss widened to $194.2 million ($1.36 per share) due to R&D and commercial launch investments, but total cash resources remained strong at $1.56 billion. On August 6, H.C. Wainwright raised its price target on Arrowhead to $120 from $115, reiterating a Buy rating, citing a one-quarter pull-forward in the plozasiran launch timeline for severe hypertriglyceridemia (SHTG) and a new partnership with Madrigal. The bull case is supported by pivotal Phase III efficacy, durable reductions in triglycerides and acute pancreatitis events, and a $1.57 billion cash balance, while the bear case centers on persistent unprofitability, with quarterly operating losses of $170.1 million in Q3, and the commercial ramp remains unproven, with REDEMPLO generating just $2.4 million in early sales. Investors should watch the full presentation of SHASTA data at the ESC Congress on August 30 and the planned sNDA filing for plozasiran before year-end 2026, alongside initial REDEMPLO reimbursement adoption metrics in Germany.
Madrigal Appoints Johnson & Johnson R&D Chief John Reed to Board
Madrigal Pharmaceuticals has appointed John C. Reed, M.D., Ph.D., to its board of directors. Dr. Reed is Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson and a member of its Executive Committee. Madrigal’s Chairman Julian Baker and CEO Bill Sibold highlighted his track record in advancing innovative medicines and his strategic leadership, which they expect will support the company’s growth and its MASH pipeline, including the launched therapy Rezdiffra.
Ribo and Madrigal Achieve First Candidate Drug Milestone in siRNA MASH Partnership
Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals, together with Madrigal Pharmaceuticals, have nominated the first drug candidate under their siRNA collaboration targeting metabolic dysfunction-associated steatohepatitis, or MASH. The milestone triggers the immediate start of IND-enabling studies to support planned clinical trials. The partnership combines Ribo’s siRNA discovery and delivery technology with Madrigal’s clinical expertise in MASH, aiming to develop novel RNA therapeutics for liver diseases with high unmet need. Both companies emphasized the rapid progress made in just a few months and their commitment to advancing the candidate toward clinical development.
Biotech & Genomic Medicine › RNAi / Antisense Oligonucleotides ▲Technology
Biotech & Genomic Medicine › Rare Disease ▲Demand
MDGL · Technology · Positive Madrigal achieves milestone in siRNA MASH partnership, advancing a drug candidate toward clinical trials.
Ribocure Pharmaceuticals AB · Technology · Positive Ribocure, as subsidiary, contributes to nomination of first drug candidate under the partnership.
Suzhou Ribo Life Science Co., Ltd. · Technology · Positive Suzhou Ribo Life Science achieves milestone in siRNA MASH partnership, advancing a drug candidate.
United States
